½Å°úÇÐ/öÇÐ
Ãʽɸ®ÇÐ/ÀáÀç´É·Â
UFO/½Å¹°¸®ÇÐ
¿ÀÄÃƼÁò/¹Ì½ºÅ͸®

°úÇÐÀû, ºñ°úÇÐÀû ÀÇÇÐ
µ¿¼­¾ç ´ëüÀÇÇÐ

âÁ¶·Ð/°úÇÐÀû »ç½Ç¼º
âÁ¶·Ð/öÇаú Á¤Ä¡

½ºÄÎƽ½º/±âŸ ÁÖÁ¦
KOPSA ¹Ú¹°°ü

 

´ëÁ߸Åü ¸ð´ÏÅ͸µ
Áú¹®°ú ´ä

Åä·Ð¹æ¹ý
Åä·Ð»ç·Ê

¿¬±¸È¸¿ø °Ô½ÃÆÇ
¿¬±¸À§¿ø °Ô½ÃÆÇ

 

Åä·Ð¹æ¹ý
   
  Á¤È²Àû ´ëÀγíÁõ ¿À·ù Circumstantial Ad Hominem (08/01/26 Ãß°¡)
  ±Û¾´ÀÌ : kopsa     ³¯Â¥ : 02-07-09 20:03     Á¶È¸ : 10250    
2008³â 1¿ù 26ÀÏ °Ô½ÃÇÑ ÀÌ ±Û°ú °ü·ÃÇÑ ¾Æ·¡ ¸µÅ©¸¦ È®ÀÎÇϽʽÿÀ.
http://www.kopsa.or.kr/gnu4/bbs/board.php?bo_table=FreeDebate&wr_id=335

Á¤È²Àû ´ëÀγíÁõ ¿À·ù Circumstantial Ad Hominem

¾Õ¼­ ´ëÀγíÁõ Áß¿¡¼­ ÇÇÀåÆÄÀå ¿À·ù¸¦ ¼³¸íÇß½À´Ï´Ù. À̹ø¿¡´Â µÎ ¹ø° Á¤È²Àû(circumstantial) ´ëÀγíÁõ ¿À·ù¸¦ ¼³¸íÇÕ´Ï´Ù. ±×¸®°í ¾ðÁ¦ ¸¶Áö¸·À¸·Î ÀνŰø°Ý¼º ¿À·ù¸¦ ´Ù·ç°Ú½À´Ï´Ù. 

1. Á¤È²Àû ´ëÀγíÁõ ¿À·ù 

Circumstantial Ad Hominem

A°¡ X¶ó´Â ÁÖÀåÀ» ÇÒ °æ¿ì AÀÇ X¿¡ ´ëÇÑ ÀÌÇسª AÀÇ Á¤È²À» ¸»ÇÏ¿© X¶ó´Â ÁÖÀåÀÌ À߸øµÆ´Ù°í ³í¹ÚÇÏ´Â °æ¿ìÀÔ´Ï´Ù. ½ÇÁ¦ Áß¿äÇÑ °ÍÀº A°¡ ÁÖÀåÇÏ´Â XÀÇ Âü ¿©ºÎÀÔ´Ï´Ù. ±× ÁÖÀåÀÇ µ¿±â¸¦ ÀǽÉÇÒ °æ¿ìµµ ÀÖÀ» °ÍÀÌÁö¸¸ ÆÇ´Ü¿¡ Á» ´õ ½ÅÁßÇØ¾ß ÇÑ´Ù´Â ´ÙÁüÀÏ »Ó AÀÇ ÁÖÀå X¿¡ ´ëÇÑ ³í¹ÚÀº XÀÇ Âü ¿©ºÎ¿¡ ±¹ÇÑÇØ¾ß ÇÕ´Ï´Ù.   

*±×´Â ±º»çºñ ÁöÃâÀ» Áõ¾×ÇØ¾ß ÇÑ´Ù°í ÁÖÀåÇÑ´Ù. ±×°ÍÀº Ʋ·È´Ù. ±×´Â °øÈ­´ç¿øÀ̱⠶§¹®¿¡ ±×·± ¸»À» ÇÒ»ÓÀÌ´Ù.

*¿ì¸®´Â Á¸½º ½ÅºÎ°¡ ³«ÅÂÀÇ À±¸®Àû ¹®Á¦¿¡ ´ëÇØ ¸»ÇÑ °ÍÀ» °ÅºÎÇØ¾ß ÇÑ´Ù. ±×´Â ±×·± °ßÇظ¦ À¯ÁöÇØ¾ß ÇÒ Àǹ«°¡ ÀÖ´Â °¡Å縯 ½ÅºÎ°¡ ¾Æ´Ï³Ä. 

*¹°·Ð ¸ÞÀÎÁÖ Ãâ½Å »ó¿øÀÇ¿øÀº Çرº ±º»çºñÀÇ °¨¼Ò¿¡ ¹Ý´ëÇÑ´Ù.  ±ºÇÔÀ» °ÇÁ¶ÇÏ´Â Á¶¼±¼Ò°¡ ¸ÞÀÎÁÖ¿¡ Àֱ⠶§¹®ÀÌ´Ù. 

*ºôÀº ±â¾÷¿¡ ´ëÇÑ ¼¼±Ý ¸éÁ¦°¡ °³¹ßÀ» Áõ°¡½Ãų °ÍÀ̶ó°í ÁÖÀåÇÑ´Ù. ºôÀº ÇÑ È¸»çÀÇ È¸ÀåÀÌ´Ï±î ±×·± ¸»À» ÇÑ´Ù.

*ÀÌÈ¥À» Âù¼ºÇÏ´Â »ç¶÷ÀÌ, ÀÌÈ¥Àº ¿©·¯ °¡Áö ÀÌÀ¯¿¡¼­ º¼ ¶§ ¿ÇÁö ¾Ê´Ù°í ¹Ý´ëÇÏ´Â ½ÅºÎ¿¡°Ô "´ç½ÅÀÌ ¾î¶»°Ô µ¶½Å »ýÈ°À» Çϸ鼭 ±×·± ÁÖÀåÀ» ÇÒ ¼ö ÀÖ½À´Ï±î?"¶ó°í ¸»Çß´Ù.

*³ëµ¿ÀÚ°¡ ³ëµ¿½Ã°£À» ´ÜÃàÇØ¾ß ÇÑ´Ù°í ÁÖÀåÇÑ °Í¿¡ ´ëÇÏ¿© "³ëµ¿ÀÚ´Â ³ëµ¿½Ã°£  ´ÜÃàÇÏ´Â °ÍÀ» ÁÖÀåÇϱ⠸¶·Ã ¾Æ´Ñ°¡"¶ó°í ¸»Çß´Ù.

2. ÁÖÀ§ °Ô½ÃÆÇ¿¡¼­ ¹ß°ßÇÑ °Í(1)

°­¹Ú»ç´Â ÇѺû³»°ú ȨÆäÀÌÁö¿Í ±×°÷°ú °ü·Ã ÀÖ¾î º¸ÀÌ´Â Àü³²ÀÇ´ë ÃÖ¿µ ±³¼öÀÇ È¨ÆäÀÌÁö¸¦ °¡²û µé¾î°¡ º¾´Ï´Ù. ³í¸® ¿À·ù µî ÀÌ·± Àú·± ÀڷḦ ¹ß°ßÇϱ⿡ ÀûÇÕÇÕ´Ï´Ù. "¼º±ÞÇÑ ÀϹÝÈ­"¿¡ ´ëÇÑ ³»¿ëÀº ÇѺû³»°ú °Ô½ÃÆÇ¿¡¼­ ¾ò¾ú°í "µ·¿¡ È£¼ÒÇÏ´Â ¿À·ù"¿Í "¹«°üÇÑ °á·Ð ¿À·ù"ÀÇ ´ëÇÑÀÇ»çÇùȸ °ü·Ã ÀÚ·á´Â ÃÖ¿µ ±³¼öÀÇ È¨ÆäÀÌÁö¿¡¼­ ¾ò¾ú½À´Ï´Ù.

ÃÖ¿µ ±³¼öÀÇ È¨ÆäÀÌÁö¿¡´Â "´ëÇѹα¹ ±âÀÚÀÇ ±Û¾²´Â ¹ý"À̶ó´Â Á¦¸ñÀÇ ±ÛµéÀÌ ¿Ã¶ó Àִµ¥, À̰͵µ "¼º±ÞÇÑ ÀϹÝÈ­"¿¡ ÇØ´çµË´Ï´Ù. ³»¿ëÀ» Àо´Ï º»Àεµ "Áö³ªÄ£ ÀϹÝÈ­"¶ó´Â °ÍÀ» ¾Ð´Ï´Ù. ±×·¯³ª ¾Ë¸é ¹«¾ùÀ» Çմϱî? ±×°ÍÀ» °íÃÄ¾ß ±× ´ÙÀ½¿¡ ÀÚ½ÅÀÇ ±ÛÀÌ »ç´Â ¹ýÀÔ´Ï´Ù. 

À̹ø¿¡ "Á¤È²Àû ´ëÀγíÁõ ¿À·ù"ÀÇ ¿¹·Î ´Ù½Ã ÃÖ¿µ ±³¼öÀÇ È¨ÆäÀÌÁö ±ÛÀ» µé°Ú½À´Ï´Ù. ¾Æ·¡ Àü¹®À» ÷ºÎÇß½À´Ï´Ù. Á¦¸ñÀÌ "Á¤º¸ÀÇ Ãâó ÀÚ¼¼È÷ º¸±â"Àε¥ "¾Æħ ¸Ô¾î¾ß ¼ö´É Á¡¼ö ³ô´Ù" ±â»ç¿¡ ´ëÇÑ ³»¿ëÀÔ´Ï´Ù. ±×´Â "ÀÌ ±â»ç¸¦ º¸°í µéÀ¸¸é¼­...Á¦ÀÏ ¸ÕÀú »ìÆ캻 °ÍÀº '´©°¡ ÀÌ ¿¬±¸¸¦ Çߴ°¡?'¿´½À´Ï´Ù. '´©°¡' ¿¬±¸¸¦ Çߴ°¡´Â '¿Ö' ¶Ç´Â '¾î¶² ¸ñÀû'À¸·Î ÀÌ ¿¬±¸¸¦ Çߴ°¡¸¦ »ìÆ캸´Â Áö¸§±æÀ̱⠶§¹®ÀÔ´Ï´Ù"¶ó°í Çß½À´Ï´Ù.

±×·¡¼­ ÀÌ ¿¬±¸¸¦ ³óÃÌÁøÈïû¿¡¼­ ÇÑ °ÍÀ» ¾Ë¾Ò°í ÇѸ¶µð·Î "½ÒÀ» ¼ÒºñÇÏÀÚ"´Â ¸ñÀû¿¡¼­ ÇàÇÑ ¿¬±¸ÀÏ °ÍÀ̶ó°í Çß½À´Ï´Ù. ±×¸®°í "¸ðµç º¸µµ¿¡´Â Á¦º¸ÀÚ³ª Á¤º¸ÀÇ Ãâó°¡ ÀÖ°Ô ¸¶·ÃÀ̹ǷÎ... ²À Ãâó¸¦ »ìÆ캸½Ã±â¸¦ ¹Ù¶ø´Ï´Ù. µ¿½Ã¿¡, ¿Ö ÀÌ·± Á¤º¸°¡ ³ª¿À°Ô µÇ¾úÀ»±îµµ »ý°¢ÇØ º¸½Ã±â¸¦ ±ÇÇÕ´Ï´Ù"¶ó°í ÇÏ¸ç ¸¶Áö¸·À¸·Î ÀÌ·¸°Ô ¸»ÇÕ´Ï´Ù. 

"°Ç°­À» ÁöÅ°±â À§ÇØ... ¾ÆħÀ» ²À ¸ÔÀÚ´Â °Í¿¡ ÇÊÀÚµµ µ¿ÀÇÇÕ´Ï´Ù. ³óÃÌÀ» »ì¸®±â À§ÇØ... °¡±ÞÀû ½Ò ¼Òºñ¸¦ ´Ã¸®´Â °Í¿¡µµ µ¿ÀÇÇÕ´Ï´Ù. ÇÏÁö¸¸, '¾Æħ ¸ÔÀ¸¸é ¼ºÀû ÁÁ¾ÆÁø´Ù'¿¡´Â µ¿ÀÇÇÏÁö ¾Ê½À´Ï´Ù. ÀÌ ºÎºÐ¿¡ ´ëÇؼ­´Â ´ÙÀ½¿¡ ´Ù·ç¾î º¸°Ú½À´Ï´Ù."

±×´Â "¾Æħ ¸ÔÀ¸¸é ¼ºÀû ÁÁ¾ÆÁø´Ù"¿¡ µ¿ÀÇÇÏÁö ¾Ê°í ´ÙÀ½¿¡ ´Ù·ç¾î º¸°Ú´Ù°í Çß½À´Ï´Ù. ±×·¸´Ù¸é ´ÙÀ½¿¡ ÇмúÀûÀ¸·Î ºÐ¼®ÇÏ¿© ¿Ã¸®´Â °ÍÀÌ ºñÆÇ ¹æ¹ýÀÔ´Ï´Ù. ÀÌ Á¤È²Àû ¸»À» ÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî¿ä? ´Ü¼øÈ÷ ÀÌ ¿¬±¸°¡ "½ÒÀ» ¼ÒºñÇÏÀÚ"´Â ³óÃÌÁøÈïûÀÇ ¿¬±¸¶ó´Â °ÍÀ» ¾Ë¸®´Â °ÍÀԴϱî? ¾Æ´Ï¸é ¹«¾ùÀΰ¡ ¿¬±¸¿¡ ¹®Á¦°¡ ÀÖÀ» °ÍÀ̶ó°í ¸»ÇÏ·Á´Â °ÍÀԴϱî? ÈÄÀÚ·Î ÀÌÇص˴ϴÙ. ÃÖ¿µ ±³¼ö°¡ Á¤È²Àû ´ëÀγíÁõ ¿À·ù¸¦ ¹üÇß´Ù°í ¸»ÇÏ°íÀÚ ÇÕ´Ï´Ù.

°­¹Ú»ç´Â "´ëÇѹα¹ ±âÀÚÀÇ ±Û¾²´Â ¹ý"À̶ó´Â Á¦¸ñ¸¸Å­ °¨Á¤ÀûÀÎ Á¦¸ñÀº ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù. °úÇÐ Àü°øÀÌ ¾Æ´Ï¶óµµ ³î¶ø°Ô °úÇÐ ±ÛÀ» Àß ¾²´Â ±âÀÚµéÀÌ ¸¹½À´Ï´Ù. À̵éÀº ´ëºÎºÐ ½À°üÀûÀ¸·Î ºñÆÇÀû »ç°í¸¦ ÇÕ´Ï´Ù. ±âÀÚµéÀ» ÇâÇÑ ¿åÀ̳ª ´Ù¸§¾ø´Â ÀÌ·± Á¦¸ñÀ̳ª ³óÃÌÁøÈïû °úÇÐÀÚµéÀÇ ¿¬±¸¸¦, À߸øÀÌ ÀÖ´Ù¸é ±× À߸øÀ» ÇмúÀûÀ¸·Î ÁöÀûÇϱâ Àü¿¡ Á¤È²ÀûÀ¸·Î ¸»ÇÏ¿© ¿åÇÏ´Â (¿åÀÔ´Ï´Ù!) ½À°üÀº À߸øµÈ °ÍÀÔ´Ï´Ù.

3. ÁÖÀ§ °Ô½ÃÆÇ¿¡¼­ ¹ß°ßÇÑ °Í(2)
(2008/01/25 ÀÌ ºÎºÐ ¿À·ùÀÇ »ç°í¿Í °ü·ÃÇÏ¿© 2.¿Í ¿¬°áµÈ °ÍÀÔ´Ï´Ù. ÀνŰø°Ý ºÎºÐÀÌ ÀÖÁö¸¸  ÀνŰø°ÝÀº º°µµ·Î ´Ù·ç¾ú½À´Ï´Ù)

ÃÖ¿µ ±³¼öÀÇ È¨ÆäÀÌÁö¿¡ ¿Ã¶ó ÀÖ´Â ÇѺû³»°ú ÇÑ»óÀ² ¿øÀåÀÇ "Re 1: ¾ð·ÐÀÇ ¹«ÀýÁ¦ÇÑ º¸µµ¸¦ °æ°èÇÑ´Ù"¸¦ »ìÆ캸°Ú½À´Ï´Ù. ±×´Â "û³âÀÇ»ç"¿¡ ½Ç¸° "¾ð·ÐÀÇ ¹«ÀýÁ¦ÇÑ º¸µµ¸¦ °æ°èÇÑ´Ù"¸¦ ¿Å°Ü °Ô½ÃÇß½À´Ï´Ù. °ü·Ã ±Û ¾Æ·¡ Àü¹®À» ÷ºÎÇß½À´Ï´Ù.

Æó¾ÏÄ¡·áÁ¦ÀÎ ÀÌ·¹»ç¿¡ °üÇÑ °ÍÀε¥, ½Ä¾àûÀÌ È¯ÀÚÅõ¾à Áß°£Á¡°Ë °á°ú Å« È¿°ú´Â ¾ø¾ú´Ù´Â ¹ßÇ¥¸¦ ÇÏÀÚ ´ëÁß¾ð·ÐµéÀº ¾Õ´ÙÅõ¾î "ÀÌ·¹»ç ±âÀûÀÇ ½Å¾à ¾Æ´Ï´Ù"¶ó´Â Ä«ÇǸ¦ ´Þ¾Ò´Âµ¥ ÀÌ´Â ÀÌÀü¿¡ "±âÀûÀÇ ½Å¾à"À̶ó°í º¸µµÇß´ø °Í°ú ´ëÁ¶ÀûÀ̶ó°í Çß½À´Ï´Ù. Ȥ½Ã ÃÖÁ¾ °á°ú°¡ µÚ¹Ù²î±â¶óµµ ÇÏ¸é ¾ð·ÐÀº ¶Ç ¾î¶² ¹ÝÀÀÀ» º¸ÀÏÁö ±Ã±ÝÇÏ´Ù¶ó´Â ¸»µµ ÀÖ½À´Ï´Ù. óÀ½ ¾î¶² º¸µµ°¡ ³ª¿Ô´ÂÁö Àá±ñ ã¾Æº¸¾Ò½À´Ï´Ù.   

Æó¾Ï Ä¡·áÁ¦ `ÀÌ·¹»ç', Ä¡·á °¡´É¼º ³ô´Ù
2002³â 05¿ù 19ÀÏ (ÀÏ) 14:38 
yskwon@yna.co.kr
 
[½Ä¾àû] ÇØ¿Ü ÀÓ»ó½ÃÇè 'ÀÌ·¹»ç' Æó¾Ï 70¸í¿¡ ¹«·áÁ¦°ø 
[¼Óº¸, »çȸ] 2001³â 12¿ù 06ÀÏ (¸ñ) 18:43
¹Ú±¤Èñ±âÀÚ khpark@hk.co.kr
 
°³¹ß ´Ü°è Æó¾Ï Ä¡·áÁ¦ ¸»±â ȯÀÚ¿¡ ¹«»ó °ø±Þ 
[¼Óº¸, »çȸ, °Ç°­/»ýÈ°] 2001³â 12¿ù 06ÀÏ (¸ñ) 17:46
¹ÚÅÂ±Õ ±âÀÚ tkpark@joongang.co.kr
 
Þª¼Ò¼¼Æ÷ Æó¾ÏȯÀÚ 70¸í¿¡ ÀÓ»ó´Ü°è ¡®À̷ʻ硯 ¹«·á°ø±Þ 
[»çȸ] 2001³â 12¿ù 06ÀÏ (¸ñ) 17:28
±è°æÈ£±âÀÚ kyungho@kmib.co.kr

óÀ½ ¾ð·ÐÀÇ º¸µµ°¡ ¾î¶°Çß´ÂÁö´Â ´ëÃæ ÀÌ°ÍÀ¸·Î ºÐÀ§±â¸¦ ¾Ë ¼ö ÀÖÀ» °ÍÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ±× ´ÙÀ½ ¸ðµÎ°¡ º¸µµÇÑ "±âÀûÀÇ ½Å¾à ¾Æ´Ï´Ù"¶ó´Â Á¦¸ñÀº º°·Î ¹®Á¦µÉ °ÍÀÌ ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù. ¿ÀÈ÷·Á ±³À°ÀûÀÔ´Ï´Ù. óÀ½ ¾î¶² ¾ð·ÐÀÌ ±âÀû ¿î¿îÇß´ÂÁö ¾Ë·ÁÁֽñ⠹ٶø´Ï´Ù. 

À̺¸´Ù °­¹Ú»ç´Â "ÃÖ±Ù ½Ä¾àûÀÌ ÀÌ·¹»çÁ¤ÀÇ È¯ÀÚÅõ¾à Áß°£Á¡°Ë °á°ú Å« È¿°ú´Â ¾ø¾ú´Ù´Â ¹ßÇ¥¸¦ ÇÏÀÚ"¶ó´Â ´ë¸ñÀ» ÀÌ»óÇÏ°Ô º¸¾Ò½À´Ï´Ù. ÀÌ·¹»çÁ¤À» Çѱ¹¿¡¼­ Åõ¾àÇß´Ù¸é ÀÓ»ó ½ÃÇèÀ̰ųª ÆǸŠÇã°¡ Àü¿¡ Ưº°ÇÑ °æ¿ì ȯÀÚ¿¡°Ô »ç¿ëÀ» ½ÂÀÎÇÑ °æ¿ìÀÔ´Ï´Ù. ÀÓ»ó 2»óÀº Áö³­ ¾àÀÏ °ÍÀÔ´Ï´Ù. ±×·±µ¥ È¿°ú°¡ ¾ø¾ú´Ù°í ¹ßÇ¥°¡ ³µÀ¸¸é ÀÓ»ó ½ÃÇèÀÌ ¾Æ´Ï¶ó Ưº°ÇÑ °æ¿ì ȯÀÚ Åõ¾à °á°úÀÏ °¡´É¼ºÀÌ Å®´Ï´Ù.

°£´ÜÈ÷ ã¾Æº¸´Ï "û³âÀÇ»ç"¿Í °°Àº ¶§ "Çѱ¹Æó¾Ï ¼¾ÅÍ"ÀÇ ÀÚ·á°¡ ÀÖ½À´Ï´Ù. ¾Æ·¡ ÷ºÎÇß½À´Ï´Ù. óÀ½ÀÌ "ÀÓ»ó½ÃÇè ´Ü°è¿¡¼­ ±¹³» Æó¾ÏȯÀÚ¿¡°Ô Àü°Ý Åõ¾àµÆ´ø ¿µ±¹°è Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«ÀÇ ºñ(Þª)¼Ò¼¼Æ÷ Æó¾ÏÄ¡·áÁ¦ 'ÀÌ·¹»ç'°¡ ´çÃÊ ±â´ëÇß´ø ¸¸Å­ `±âÀûÀûÀÎ' Ä¡·á È¿°ú¸¦ º¸ÀÌÁö ¸øÇÏ°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù"¶ó°í µÅ ÀÖÀ¸³ª Á¦ÀÏ ³¡ÀÇ Á¦¾àȸ»çÀÇ ¸»À» ÀοëÇÑ ´ÙÀ½°ú °°Àº ´ë¸ñÀÌ Á¤È®ÇÏ´Ù°í º¾´Ï´Ù.

"Çѱ¹¾Æ½ºÆ®¶óÁ¦³×Ä«´Â 'Çѱ¹¿¡¼­ÀÇ ÀÌ·¹»ç Åõ¾à °á°ú´Â ±âÁ¸ È­Çпä¹ýÀ¸·Î´Â ´õ ÀÌ»ó Ä¡·áÇÒ ¼ö ¾ø´Â ³­Ä¡¼º ¸»±â Æó¾ÏȯÀÚµéÀ» ´ë»óÀ¸·Î ÀÌ·ïÁø °ÍÀ¸·Î Á¤½Ä ÀÓ»ó½ÃÇè°á°ú°¡ ¾Æ´Ï´Ù'¸é¼­ 'ÀÌ¿¡ µû¶ó ÀÌ °á°ú¸¦ °¡Áö°í ÀÌ·¹»çÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» ¼Ó´ÜÇؼ­´Â ¾È µÈ´Ù'°í ¸»Çß´Ù."

"´õ ÀÌ»ó Ä¡·áÇÒ ¼ö ¾ø´Â ³­Ä¡¼º ¸»±â Æó¾Ï ȯÀÚ"¸¦ ´ë»óÀ¸·Î ÇÑ °Í °°½À´Ï´Ù. ÀÌ°ÍÀ¸·Î ¾àÀÇ È¿°ú°¡ ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù°í ÀÌ·¹»çÀÇ È¿°ú°¡ ¾ø´Ù°í´Â ÇÒ ¼ö ¾ø°ÚÁö¿ä. ±×¸®°í 2002³â 7¿ù 5ÀÏ ÀÌ·¹»ç°¡ ÀϺ»¿¡¼­ ÆǸŠÇã°¡°¡ ³µ´Ù´Â ±â»ç¸¦ ¹ß°ßÇß½À´Ï´Ù. ¾Æ·¡ Àü¹®À» ÷ºÎÇÕ´Ï´Ù. ¹Ì±¹ FDAÀÇ Çã°¡°¡ ³¯ °ÍÀÎÁö, ÀÌ·¹»çÀÇ È¿´É¼º ¾ÈÀü¼º ÀÚ·á°¡ ¾î¶²Áö Á¤È®ÇÑ °ÍÀº ãÁö ¾Ê¾ÒÀ¸³ª ¼ö¼úÀÌ ºÒ°¡´ÉÇÑ ¶Ç´Â Àç¹ß¼º ºñ¼Ò¼¼Æ÷ Æó¾Ï(NSCLC)¿¡ Ưº°ÇÑ ¾àÀ¸·Î º¸ÀÔ´Ï´Ù. 

¾ð·ÐÀÇ ÀÌ·¹»ç º¸µµ ŵµ°¡ "¾ð·ÐÀÇ ¹«ÀýÁ¦ÇÑ º¸µµ¸¦ °æ°èÇÑ´Ù"°¡ µÉ °ÍÀÎÁö´Â ÀÌ ±ÛÀ» Àд ºÐµéÀÌ ÆÇ´ÜÇϽñ⠹ٶø´Ï´Ù. ¼­·ÐÀÌ ±æ¾ú´ÂÁö ¸ð¸£³ª ÀÌ ±ÛÀ» ÀûÀº ÀÌÀ¯´Â ÇÑ»óÀ² ¿øÀåÀ̳ª ÃÖ¿µ ±³¼ö¿¡°Ô ³í¸® ¿À·ù Áß¿¡¼­ °¡Àå ³ª»Û °ÍÀÌ ´ëÀγíÁõ Áß¿¡¼­ Àνźñ¹æÀ̶ó´Â °ÍÀ» ¸»ÇÏ·Á´Â °ÍÀÔ´Ï´Ù. ÁÖÀå°ú´Â °ü·ÃÀÌ ¾øÀÌ ÁÖÀåÀÚ¸¦ ºñ¹æÇÏ¿© ±× ÁÖÀåÀ» ¾àÇÏ°Ô º¸ÀÌ°Ô ÇÏ´Â °ÍÀÌ Àνźñ¹æÀÔ´Ï´Ù.

¿¹¸¦ µé¾î "Àú ÇÑ»óÀ² »çÀ̺ñ´Ù. ±×°¡ ȨÆäÀÌÁö¿¡ Àû¾î ³õÀº °Í ´Ù ¹ÏÀ» °ÍÀÌ ¾ø´Ù"¶ó´Â ½ÄÀÌ Àνźñ¹æÀÔ´Ï´Ù. ÇÑ¿øÀåÀÌ Àû¾î ³õÀº °ÍÀ» À߸øµÇ¾ú´Ù°í º¸°Å³ª ºÒ¸¸ÀÌ¸é ¹Ù·Î ±× Àû¾î ³õÀº °ÍÀ» ³íÁõÀ» ÅëÇØ À߸øµÆ´Ù°í Áõ¸íÇÏ¸é µÇ´Â °ÍÀÔ´Ï´Ù. ÃÖ¿µ ±³¼ö´Â °Ô½ÃÆÇ¿¡¼­ Àǻ縦 ÇâÇÑ ½Ö¿åÀ» ÁöÀûÇßÁö¸¸ »ç½Ç»ó ÀÌ·¯ÇÑ Àνźñ¹æº¸´Ù´Â ½Ö¿åÀÌ ³´½À´Ï´Ù. ½Ö¿åÀ̶ó¸é ´©±¸³ª »ó´ëÆíÀÌ ÇüÆí¾ø´Â ÁÙ ¾ËÁö¸¸ »çÀ̺ñ´Ù ¾î¶»´Ù´Â ½ÄÀÇ ºñ¹æÀº ´çÀå À߸øµÆ´Ù°í º¸Áö ¾ÊÀ» »ç¶÷µµ Àֱ⠶§¹®ÀÔ´Ï´Ù.

ÀÌ°÷¿¡¼­ ¸»ÇÏ·Á´Â °ÍÀº ¾Õ¼­ ÇѺû³»°ú °Ô½ÃÆÇ ÀÏÀÔ´Ï´Ù. ÇÑ»óÀ² ¿øÀåÀÌ °­¹Ú»çÀÇ ÇÑ°Ü·¹21ÀÇ ºñŸ¹Î C Ä®·³À» °Ô½ÃÇÑ °ÍÀ» º¸°í ±èÁø¸¸ÀÌ DalsolÀ̶ó´Â À§Àå ID·Î ¹«¾ùÀ̶ó°í ÅäÀÇÇÑ ³»¿ëÀº ¾Õ¼­ °Ô½ÃÇß½À´Ï´Ù. ±èÁø¸¸ÀÇ Ã¹ ¸»ÀÌ "ÀÌ·± °Í ¸®ºä¸¦ º¸¸é ¾Ð´Ï´Ù"¿´½À´Ï´Ù. ±×´Â Quackwatch¸¦ ÀÐÀº °ÍÀ» ÀÚ¶û½º·´°Ô ÀÌ·¸°Ô ¸»Çϸç Quackwatch¿¡¼­ È¿°ú°¡ ¾ø´Ù°í Çϴµ¥ ¹«¾ùÀ̶ó°í ´Ù¸¥ ¸»À» Çß´Ù°í Ʋ·È´Ù°í Çß½À´Ï´Ù.

35¼¼ÀÇ ³ªÀÌ¿¡ ¾î´À Á¤µµÀÇ ÁöÀû ´É·ÂÀÌ Á¤»óÀÎÁö ¾ËÁö ¸øÇϳª ÀÌ·¸°Ô ÀڽŠÀÖ°Ô ¸»ÇÏ¸ç ¹«¾ùÀ̶ó°í ÇÑ °ÍÀ» º¸°í ±×°¡ ºñÁ¤»óÀûÀÎ ÁöÀû °áÇÌ »óŶó°í »ý°¢Çß½À´Ï´Ù. ´õ¿íÀÌ "ÀÌ°Ô °­°ÇÀϾ¾ ÀÔ´Ï´Ù"¶ó°í Çϸç Àû¾î ³õÀº ºÎºÐÀ» º¸¾Æµµ, ÀÌ°÷ Åä·Ð »ç·Ê¿¡ ÀÚ¼¼È÷ ºÐ¼®ÇØ ³õÀº °ÍÀ» ÀÐÁö ¾Ê´õ¶óµµ ±×´Â ºñÆÇÀÌ´Ï ±×·± °ÍÀ» ÇÒ Á¤½Å »óÅ°¡ µÇÁö ¸øÇÕ´Ï´Ù. ¸î ³â°£ ¼ö¾øÀÌ ºÐ¼®ÇÑ °á°ú Á¤½Åº´¸®Àû ¹®Á¦, Á¤½ÅÀÌ»óÀ¸·Î º¼ ¼ö¹Û¿¡ ¾ø´Ù°í ÇÏÁö ¾Ê¾Ò½À´Ï±î. (2008/01/25 Á¤½ÅÀÌ»óÀº Á¤½ÅÀûÀ¸·Î ºñÁ¤»óÀ̶ó´Â ÀǹÌÀÔ´Ï´Ù)

°­¹Ú»ç´Â ÇÑ»óÀ² ¿øÀåÀÌ Àû¾îµµ º¸Åë»ç¶÷ÀÇ ¾ç½ÄÀ» °¡Á³´Ù¸é ±× ±ÛÀ» »èÁ¦Çß¾î¾ß ÇÒ °ÍÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. °­¹Ú»ç°¡ ³öµÎ¶ó°í Çصµ ±×·¸°Ô ÇØ¾ß ºñÆÇÀÌ´Ï ¹¹´Ï ¶°³ª ±×Àú ¾ç½ÄÀÌ ÀÖ´Â »ç¶÷À̶ó´Â ¸»À» µéÀ» ¼ö ÀÖ´Â °ÍÀÔ´Ï´Ù. ±×·± ¾ç½ÄÀÌ ¾øÀ¸¸ç ±èÁø¸¸°ú ¾î±úµ¿¹«¸¦ ÇÏ¸ç ³ë´Â ÇÑ»óÀ² ¿øÀåÀ̳ª ±èÁø¸¸°ú °Å¸®¸¦ µÎÁö ¾Ê´Â ÃÖ¿µ ±³¼ö¸¦ º¸¸ç À̵éÀÌ ´©±¸ÀÎÁö, ºñÆÇÀû »ç°í ´É·ÂÀ» °¡Á³´ÂÁö Àǽɵȴٴ ¶æÀ¸·Î ÀÌ ±ÛÀ» Àû¾ú½À´Ï´Ù.
   
.............................. 
[»çȸºñÆò] "Äû³×¿¡" ¹þ±â±â
¼º¸í: ÃÖ¿µ
2002/07/09 15:35:50 
Á¤º¸ÀÇ Ãâó ¹Ù·Î º¸±â

¸¹Àº ºÎ¸ðµéÀÌ ÀÚ³àÀÇ ÇнÀ°ú ¼ºÀû¿¡ °ü½ÉÀÌ ¸¹½À´Ï´Ù. °øºÎÇÏ´Â ´ç»çÀڵ鵵 ´ëºÎºÐ ±×·² °ÍÀÔ´Ï´Ù. ±×·± Á¡¿¡¼­, ÀÌ ±â»ç´Â Çлý, ºÎ¸ð ±×¸®°í ±³»çµé¿¡°Ô ´«À» ¹ø½ ¶ßÀÌ°Ô ÇÏ´Â ¸Å·ÂÀûÀÎ Á¤º¸ÀÓ¿¡ Ʋ¸²¾ø½À´Ï´Ù. ¼Ò¾Æû¼Ò³âÀ» Áø·áÇÏ´Â Á¤½Å°ú ÀÇ»ç·Î¼­, ±×¸®°í ÇÑ »ç¶÷ÀÇ ºÎ¸ð·Î¼­ Àú ¿ª½Ã ¸¶Âù°¡Áö¿´´ä´Ï´Ù.

"¾Æħ ¸Ô¾î¾ß ¼ö´É Á¡¼ö ³ô´Ù", "¾Æħ ¸Ô¾î¾ß ¼ö´É °íµæÁ¡", ±×¸®°í "¾Æħ ¸ÔÀ¸¸é ¼ºÀû ÁÁ¾ÆÁø´Ù"¶ó´Â Á¦¸ñÀÇ º¸µµ¸¦ Á¢ÇÑ ´ëºÎºÐÀÇ »ç¶÷µéÀº ¾Æ¸¶ ÀÌ ¿¬±¸ÀÇ °á°ú¸¸À» ±â¾ïÇÒÁöµµ ¸ð¸£°Ú½À´Ï´Ù. ±×·¡¼­ ´ÙÀ½³¯ ¾ÆħºÎÅÍ "°øºÎ Àß ÇÏ·Á¸é ¾ÆħÀ» ²À ¸Ô¾î¶ó", "½Å¹® ¹æ¼Û¿¡ ³µ´õ¶ó", "¿¬±¸ °á°ú°¡ ±×·¸´ÙÀÝ´Ï..." ½ÄÀÇ ¸»À» Àڳ࿡°Ô ÇÑ »ç¶÷µéÀÌ ÀÖÀ» °ÍÀ¸·Î ¹Ì·ç¾î ÁüÀÛÇØ º¾´Ï´Ù.

Àú´Â Á¶±Ý ´Þ¶ú½À´Ï´Ù. ÀÌ ±â»ç¸¦ º¸°í µéÀ¸¸é¼­... Á¦°¡ Á¦ÀÏ ¸ÕÀú »ìÆ캻 °ÍÀº "´©°¡ ÀÌ ¿¬±¸¸¦ Çߴ°¡?"¿´½À´Ï´Ù. "´©°¡" ¿¬±¸¸¦ Çߴ°¡´Â "¿Ö" ¶Ç´Â "¾î¶² ¸ñÀû"À¸·Î ÀÌ ¿¬±¸¸¦ Çߴ°¡¸¦ »ìÆ캸´Â Áö¸§±æÀ̱⠶§¹®ÀÔ´Ï´Ù.

º¸µµµÈ °Íó·³ ¿¬±¸¸¦ ½ÃÇàÇÑ ´ç»çÀÚ´Â ³óÃÌÁøÈïûÀÔ´Ï´Ù. º¸µµÀÇ Ãâó ¿ª½Ã "2002³â »ó¹Ý±â ³óÃÌÁøÈïû ¾÷¹«Æò°¡"¶ó´Â Á¦¸ñÀÇ ¾ð·ÐÈ«º¸ÀÚ·áÀÔ´Ï´Ù. Á¶±Ý ´õ ¾ð·ÐÈ«º¸ÀڷḦ Àо¸é "³óÃÌÁøÈïûÀåÀÌ ³ó¸²ºÎÀå°ü¿¡°Ô 2002³â »ó¹Ý±â ¾÷¹«Æò°¡ °á°ú¸¦ º¸°íÇϸ鼭 ´ëÀÔ¼öÇè»ýµéÀÇ ¾Æħ½Ä»ç°¡ ¼ö´É¼ºÀû°ú ³»½Å¼ºÀû¿¡ Å©°Ô ¿µÇâÀ» ¹ÌÄ£´Ù°í ¹àÇû´Ù"´Â °ÍÀÔ´Ï´Ù.

³óÃÌÁøÈïû ȨÆäÀÌÁö(http://www.rda.go.kr/)¿¡¼­ ¹àÈù ³óÃÌÁøÈïûÀÇ ÀÓ¹«´Â ´ÙÀ½°ú °°½À´Ï´Ù.

-³ó¾÷°úÇбâ¼ú¿¡ °üÇÑ ¿¬±¸°³¹ß
-¿¬±¸°³¹ßµÈ ³ó¾÷°úÇбâ¼úÀÇ º¸±Þ.Áöµµ
-ºñ·á.³ó¾à ¹× ³ó±â°èÀÇ Ç°Áú°ü¸®
-Áö¿ª³ó¾÷ ¹ßÀü°ú »ýÈ°°³¼±¿¡ °üÇÑ Áöµµ.±³À° ¹× Àü¹®³ó¾÷ÀÎ À°¼º

±»ÀÌ ÀÌ ÀÓ¹«¸¦ ÀоÁö ¾Ê´õ¶óµµ, ³óÃÌÁøÈïûÀÌ ¿Ö ÀÌ ¿¬±¸¸¦ ½ÃÇàÇß´Â °¡¸¦ ¹Ì·ç¾î ÁüÀÛÇØ º¼ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¿¬±¸ÀÇ ½ÃÇàÀÚµéÀº "¼ºÀû" º¸´Ù´Â "¾Æħ½Ä»ç"¿¡ ¹«°ÔÁß½ÉÀ» µÐ ±¹°¡±â°üÀÇ Á¾»çÀÚ¶ó´Â °ÍÀÔ´Ï´Ù.

ÁüÀÛÀÌ ¾ÈµÇ½Å´Ù°í¿ä? ±×·³, À§¿¡ ÀοëµÈ ±â»çÀÇ ÇÑ ºÎºÐÀ» ´Ù½Ã Àо½Ê½Ã¿À. ³óÁøû ³óÃÌ»ýÈ°¿¬±¸¼Ò °¡Á¤°æ¿µ°úÀåÀÇ ¸»ÀÔ´Ï´Ù.

"°ÇÀüÇÏ°í ±ÔÄ¢ÀûÀÎ ¾Æħ½Ä»ç´Â ¼öÇè»ý»Ó¸¸ ¾Æ´Ï¶ó ÀϹÝÀÎÀÇ °Ç°­À» À¯ÁöÇϱâ À§Çؼ­ ÇʼöÀû... ƯÈ÷ ¿ì¸® ÁÖ½ÄÀÎ ½ÒÀÇ ÀüºÐÀº ³úÈ°µ¿À» ÃËÁø½Ãų ¼ö ÀÖÀ¸¹Ç·Î ½ÒÀ» ÁÖÃàÀ¸·Î ÇÑ ¾Æħ ½Ä´ÜÀº ¼öÇè»ý¿¡°Ô Å« µµ¿òÀ» ÁÙ °Í..."

±×·¸½À´Ï´Ù. ÀÌ ¿¬±¸ÀÇ ¹è°æ¿¡´Â "½ÒÀ» ¼ÒºñÇÏÀÚ"°¡ ÀÖ½À´Ï´Ù.

ÃÖ±Ù ½ÒÀÇ ¼Òºñ°¡ ÁÙ¾ú´Ù°í ÇÕ´Ï´Ù. ±×·¡¼­ÀÎÁö ½É½ÉÄ¡ ¾Ê°Ô ¾ð·ÐÀ» ÅëÇØ "½ÒÀº ¿ì¸® ¹ÎÁ·ÀÇ ¿µ¿øÇÑ ¿¡³ÊÁö¿ø... ½ÄÀÌ(ãÝìÈ)¼¶À¯´Â ¹°·Ð ´Ü¹éÁú¡¤Áö¹æ¡¤ºñŸ¹ÎÀÌ Ç³ºÎÇØ °Ç°­À» ÁöÄÑÁÖ´Â »ý¸í¿ø... ³ª¾Æ°¡ ¼ºÀκ´À» ¾ïÁ¦ÇÏ´Â ¼ººÐµéÀÌ ÀÖ´Ù"´Â ¿¬±¸ °á°úµéÀÌ º¸µµµÇ°ï ÇÕ´Ï´Ù. ÀÌ·± ÀÏ·ÃÀÇ ¿¬±¸¿Í º¸µµ ¸¦ "½ÒÀÇ ¼Òºñ¸¦ ÃËÁøÇϱâ À§ÇÑ ³ë·Â"À¸·Î ¹Þ¾ÆµéÀδٸé, Áö³ªÄ£ °ÍÀϱî¿ä?

ÇÊÀÚ´Â ÀÌ·± ½Ò ¼Òºñ¸¦ Àå·ÁÇÏ´Â ¿¬±¸¿Í ±â»ç¸¦ Á¢Çϸ鼭 ÃʵîÇб³(´ç½Ã¿¡´Â ±¹¹ÎÇб³) ½ÃÀýÀÇ µµ½Ã¶ô °Ë»ç¸¦ ¶°¿Ã¸®°ï ÇÕ´Ï´Ù. 1960³â´ë¿¡´Â º¸¸®¿Í ¹ÐÀÌ ¾ó¸¶³ª ¸ö¿¡ ÁÁÀº°¡¸¦ È«º¸Çϸ鼭, º¸¸®¸¦ ÀÏÁ¤·® ¼¯¾î ¸Ôµµ·Ï ±ÇÀåÇß´ø ÀûÀÌ ÀÖ½À´Ï´Ù. ½Ò¹ä¸¸ ¸ÔÀ¸¸é °Ç°­¿¡ ÁÁÁö ¾Ê´Ù´Â Çù¹Ú(?)µµ ±â¾ïÇÕ´Ï´Ù. ¼±»ý´Ô¿¡°Ô È¥ÀÌ ³ªÁö ¾Ê±â À§Çؼ­, º¸¸®½ÒÀ» µµ½Ã¶ô À§ÂÊÀ¸·Î ¸ðÀ¸´ø ¶Ç·¡µéÀÇ ¸ð½Àµµ »ý»ýÇÕ´Ï´Ù.

ƯÁ¤ÇÑ Àã´ë¿¡ µû¶ó¼­ ½ÒÀÌ °Ç°­¿¡ ³ª»Ú´Ù°í ¸»ÇØ ³õ°í´Â, ³ªÁß¿¡´Â ÁÁ¾ÆÁø´Ù°í ÁÖÀåÇÏ°í.... ÀÌ·¡¼­¾ß µÇ°Ú½À´Ï±î?

¾ð·Ð¿¡ º¸µµµÈ ±â»ç¸¦ ÀÖ´Â ±×´ë·ÎÀÇ »ç½Ç·Î ¹Ï´Â »ç¶÷µéÀÌ ¸¹½À´Ï´Ù. ±×·± ½Å·Ú¼º°ú ¿µÇâ·Â ¶§¹®¿¡ ¾ð·ÐÀ» Á¦4, Á¦5ÀÇ ±Ç·Â±â°üÀ¸·Î ºÒ¸®±âµµ ÇÕ´Ï´Ù. ÇÏÁö¸¸, ¾Õ¿¡¼­ ¾ð±ÞÇÑ ¿¹¿¡¼­ »ý°¢ÇØ º» °Íó·³... ¾ð·ÐÀÇ º¸µµ ³»¿ëÀ» Á¦´ë·Î Æò°¡Çϱâ À§Çؼ­ ¹Ýµå½Ã »ìÆ캸¾Æ¾ß ÇÏ´Â °ÍÀÌ ÀÖ½À´Ï´Ù.

¸ðµç º¸µµ¿¡´Â Á¦º¸ÀÚ³ª Á¤º¸ÀÇ Ãâó°¡ ÀÖ°Ô ¸¶·ÃÀ̹ǷÎ... ²À Ãâó¸¦ »ìÆ캸½Ã±â¸¦ ¹Ù¶ø´Ï´Ù. µ¿½Ã¿¡, ¿Ö ÀÌ·± Á¤º¸°¡ ³ª¿À°Ô µÇ¾úÀ»±îµµ »ý°¢ÇØ º¸½Ã±â¸¦ ±ÇÇÕ´Ï´Ù.

°Ç°­À» ÁöÅ°±â À§ÇØ... ¾ÆħÀ» ²À ¸ÔÀÚ´Â °Í¿¡ ÇÊÀÚµµ µ¿ÀÇÇÕ´Ï´Ù. ³óÃÌÀ» »ì¸®±â À§ÇØ... °¡±ÞÀû ½Ò ¼Òºñ¸¦ ´Ã¸®´Â °Í¿¡µµ µ¿ÀÇÇÕ´Ï´Ù. ÇÏÁö¸¸, "¾Æħ ¸ÔÀ¸¸é ¼ºÀû ÁÁ¾ÆÁø´Ù"¿¡´Â µ¿ÀÇÇÏÁö ¾Ê½À´Ï´Ù. ÀÌ ºÎºÐ¿¡ ´ëÇؼ­´Â ´ÙÀ½¿¡ ´Ù·ç¾î º¸°Ú½À´Ï´Ù.

................................
[»çȸºñÆò] "Äû³×¿¡" ¹þ±â±â
¼º¸í: ÇÑ»óÀ²
2002/06/18 14:46:11 
Re 1: ¾ð·ÐÀÇ ¹«ÀýÁ¦ÇÑ º¸µµ¸¦ °æ°èÇÑ´Ù 

[±âÀÚ¼öø] ¾ð·ÐÀÇ ¹«ÀýÁ¦ÇÑ º¸µµ¸¦ °æ°èÇÑ´Ù
¸ð ÀÏ°£Áö´Â Áö³­´Þ ¾ÏÀÇ »õ·Î¿î Ä¡·á¹ýÀ» ÁÖÁ¦·Î ¡®ÀÌ·¹»ç¡¯ÀÇ ¿ì¼öÇÑ È¿´É¿¡ ´ëÇØ ¾ð±ÞÇß´Ù. ±×·¯³ª ÃÖ±Ù ½Ä¾àûÀÌ ÀÌ·¹»çÁ¤ÀÇ È¯ÀÚÅõ¾à Áß°£Á¡°Ë °á°ú Å« È¿°ú´Â ¾ø¾ú´Ù´Â ¹ßÇ¥¸¦ ÇÏÀÚ ´ëÁß¾ð·ÐµéÀº ¾Õ´ÙÅõ¾î ¡®ÀÌ·¹»ç ±âÀûÀÇ ½Å¾à ¾Æ´Ï´Ù¡¯¶ó´Â Ä«ÇÇ¿Í ÇÔ²² ÀÌ·¹»çÁ¤ÀÇ ¾àÈ¿¿¡ ºÎÁ¤ÀûÀÎ ÀÔÀåÀ» ÃëÇß´Ù. ¡®±âÀûÀÇ ½Å¾à¡¯À̶ó°í º¸µµÇß´ø ½Å¹® ¶ÇÇÑ ¸¶Âù°¡Áö¿´´Ù.

ÀÌ·¹»ç°¡ ±¹³»¿¡ óÀ½ µµÀ﵃ ´ç½Ã ¾ð·ÐÀÇ º¸µµ´Â ´ë´ÜÇß´ø °ÍÀ¸·Î ±â¾ïµÈ´Ù. ´ç½Ã ¾ð·ÐµéÀº ¾Õ´ÙÅõ¾î ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÄ¡·á¿¡ ±âÀûÀÇ ½Å¾àÀÌ ³ªÅ¸³µ´Ù°í º¸µµÇßÀ¸¸ç, Æó¾ÏÀ» ¾Î°í ÀÖ´ø ȯÀÚµéÀº »îÀÇ Èñ¸ÁÀ» ÀâÀº µí ¾Õ´ÙÅõ¾î ÁÖÄ¡Àǵ鿡°Ô ó¹æÀ» ¿ä±¸ÇÏ°í ³ª¼­±âµµ Çß´Ù.

ÇÏÁö¸¸ ÀÌ·¹»ç´Â ÀÓ»ó 3»óÀ» ³²°Ü ³õÀº »óÅ¿´À¸¸ç, ±ØÈ÷ Á¦ÇÑµÈ È¯Àڵ鿡°Ô¸¸ Á¦°øµÉ ¼ö ÀÖ¾ú´Ù. ´ç½Ã¿£ ÇØ´ç ºÐ¾ß Àü¹®ÀǵéÁ¶Â÷ ÀÌ·¹»ç¿¡ ´ëÇØ Àß ¾ËÁö ¸øÇÏ´Â »óÅ¿´°í, Á¦Á¶»ç ¶ÇÇÑ ¿ÜºÎ¿¡ ¾ð±ÞÁ¶Â÷ ÇÏÁö ¾Ê¾Ò¾ú´Ù. ¾ð·Ð º¸µµ ÀÌÈÄ È¯ÀÚµéÀÇ ÀüÈ­°¡ Á¦Á¶»ç·Î ºø¹ßÃÆ°í, ȯÀÚµéÀº ¡®»ª¡¯À» ½á¼­¶óµµ ÀÌ·¹»ç¸¦ ó¹æ ¹ÞÀ¸·Á µ¿ºÐ¼­ÁÖÇß´Ù.

´ç½Ã ÀÇ»çµéÀº ¾ð·Ðº¸µµ°¡ ¿ÀÈ÷·Á ÀÇ»ç¿Í ȯÀÚ°£ÀÇ ºÒ½ÅÀ» Á¶ÀåÇßÀ¸¸ç, ÀÇ»ç¼ÒÅëÀ» ´ÜÀý½ÃÄ×´Ù°í ºÒ¸¸À» Åä·ÎÇß¾ú´Ù. ÇÏÁö¸¸ ±×·ÎºÎÅÍ ºÒ°ú 6°³¿ù µÚ ±× ¡®±âÀûÀÇ ½Å¾à¡¯Àº ¾ð·Ð¿¡ ÀÇÇØ Ã¶ÀúÈ÷ ³­µµÁú´çÇÏ°í ÀÖ´Ù. Ȥ½Ã ÃÖÁ¾ °á°ú°¡ µÚ¹Ù²î±â¶óµµ ÇÏ¸é ¾ð·ÐÀº ¶Ç ¾î¶² ¹ÝÀÀÀ» º¸ÀÏÁö ±Ã±ÝÇÏ´Ù.

Àü¹®ºÐ¾ß, ƯÈ÷ »ý¸íÀ» ´Ù·ç´Â ºÐ¾ß¿¡¼­ °ËÁõµÇÁö ¾ÊÀº º¸µµ´Â ¿ÀÈ÷·Á ±¹¹ÎµéÀ» Èñ¸ÁÀÌ ¾Æ´Ñ ´õ Å« Àý¸ÁÀ¸·Î ¸ô°í °¥ ¼ö ÀÖ´Ù´Â Á¡À» ºÐ¸í ¸í½ÉÇØ¾ß ÇÒ °ÍÀÌ´Ù.

°û»óÈñ ±âÀÚ opensky@
û³âÀÇ»ç 2002-6-17
 
------------------
Á¦      ¸ñ  "Æó¾ÏÄ¡·áÁ¦ "ÀÌ·¹»ç" ±âÀûÀÇ ½Å¾à ¾Æ´Ï´Ù" 
Çѱ¹Æó¾Ï¼¾ÅÍ
ÀÛ ¼º ÀÏ  02-06-11 ¿ÀÈÄ 5:00:36 
 
ÀÓ»ó½ÃÇè ´Ü°è¿¡¼­ ±¹³» Æó¾ÏȯÀÚ¿¡°Ô Àü°Ý Åõ¾àµÆ´ø ¿µ±¹°è Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«ÀÇ ºñ(Þª)¼Ò¼¼Æ÷ Æó¾ÏÄ¡·áÁ¦ `ÀÌ·¹»ç'°¡ ´çÃÊ ±â´ëÇß´ø ¸¸Å­ `±âÀûÀûÀÎ' Ä¡·á È¿°ú¸¦ º¸ÀÌÁö ¸øÇÏ°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

4ÀÏ ½ÄÇ°ÀǾàÇ°¾ÈÀüû¿¡ µû¸£¸é ÇØ¿Ü¿¡¼­ ÀÓ»ó½ÃÇèÁßÀÎ ÀÌ·¹»ç´Â °³¹ß»çÀÎ ¾Æ½ºÆ®¶óÁ¦³×Ä«°¡ Àü¼¼°èÀûÀ¸·Î ½Ç½ÃÇÏ°í ÀÖ´Â µ¿Á¤Àû »ç¿ë¿ä¹ý °èȹ¿¡ µû¶ó Áö³­ÇØ 12¿ù¸» ±¹³» ¸»±â ºñ¼Ò¼¼Æ÷ Æó¾ÏȯÀÚ 70¸í¿¡°Ô ¹«·á·Î Åõ¾àµÆ´Ù.

´ç½Ã ½Ä¾àûÀº ÀÌ ¾àÀÌ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ ¿ÏÀüÈ÷ È®ÀεÇÁö ¾ÊÀº ÀÓ»ó½ÃÇè ´Ü°èÀε¥µµ Åõ¾àÀ» Çã¿ëÇß¾ú´Ù. ÀÌ´Â ±âÁ¸ Ä¡·á¹ýÀ¸·Î´Â Ä¡·á°¡ ºÒ°¡´ÉÇÑ Æó¾ÏȯÀÚ¿¡°Ô ÀεµÀû Â÷¿ø¿¡¼­ ¸¶Áö¸·À¸·Î Ä¡·á ±âȸ¸¦ ÁÖ±â À§Çؼ­¿´´Ù´Â °ÍÀÌ ½Ä¾àûÀÇ ¼³¸íÀÌ´Ù.

ƯÈ÷ ½Ä¾àûÀº ÀÌ·¹»çÀÇ ±¹³» °ø±Þ¹°·®ÀÌ ÇÑÁ¤µÅ ÀÖ´Â Á¡À» °¨¾ÈÇØ ±¹¸³¾Ï¼¾ÅÍ ÀÌÁø¼ö ¹Ú»ç µî Æó¾ÏÀü¹®°¡ 6¸íÀ¸·Î º°µµÀÇ ½ÉÀÇÀ§¿øȸ¸¦ ±¸¼º, ¾ö°ÝÇÑ ½É»ç±âÁØ¿¡ µû¶ó Åõ¾à´ë»ó ȯÀÚ 70¸íÀ» ¼±Á¤Çß´Ù.

¼±Á¤±âÁØ¿¡ µû¶ó Æó¾Ï ÀÌ¿ÜÀÇ ´Ù¸¥ ¾Ç¼ºÁ¾¾çÀÌ Àְųª ¹æ»ç¼± Ä¡·á ¶Ç´Â ´Ù¸¥ Àü½ÅÀû Ç×¾ÏÄ¡·á¸¦ ¹Þ°í ÀÖ´Â °æ¿ì, ´Ù¸¥ ÀÓ»ó½ÃÇè¿ë ÀǾàÇ°À» Åõ¾à¹Þ°í ÀÖ´Â °æ¿ìµîÀº ¼±Á¤´ë»ó¿¡¼­ Á¦¿ÜµÆ´Ù.

±×·¯³ª ½Ä¾àûÀº ÀÌ·¹»ç¸¦ 1¡­5°³¿ù Åõ¾à¹ÞÀº ¸»±â Æó¾ÏȯÀÚ °¡¿îµ¥ 19¸íÀÌ »ç¸ÁÇÏ°í, 18¸íÀÌ »ç¿ë Áß´ÜÇß´Ù°í ¹àÇû´Ù. ¶Ç 3¸íÀº Ä¡·á¿©ºÎ°¡ È®ÀεÇÁö ¾Ê°í Àִ°ÍÀ¸·Î ³ªÅ¸³µ´Ù°í ½Ä¾àûÀº µ¡ºÙ¿´´Ù. ÀÌ¿Í ÇÔ²² Áö±Ý±îÁö ÀÌ·¹»ç¸¦ °è¼Ó ¹«·á°ø±Þ¹Þ°í Àִ ȯÀÚ´Â 33¸í¿¡ ±×Ä¡´Â °ÍÀ¸·Î Á¶»çµÆ´Ù.

Àü¹®°¡µéÀº "ÀÌ·¹»ç´Â ¾Ï¼¼Æ÷ Áõ½ÄÈ¿¼ÒÀΠƼ·Î½Å Å°³ªÁ¦ÀÇ È°µ¿À» ¼±ÅÃÀûÀ¸·Î¾ïÁ¦, ¼¼Æ÷ ³»·Î Àü´ÞµÇ´Â ½ÅÈ£¸¦ Â÷´ÜÇÔÀ¸·Î½á ¾Ï¼¼Æ÷ Áõ½ÄÀ» ¸·µµ·Ï ¼³°èµÆ´Ù´ÂÁ¡¿¡¼­ ±âÁ¸ Ç×¾ÏÁ¦¿Í ´Ù¸£´Ù"¸é¼­ "±×·¯³ª Ä¡·á È¿°ú Ãø¸é¿¡¼­ ±âÀûÀÇ ½Å¾àÀÌ µÉ°ÍÀ¸·Î ±â´ëÇÏ´Â °ÍÀº ¾ÆÁ÷ ¹«¸®"¶ó°í Æò°¡Çß´Ù.

Çѱ¹¾Æ½ºÆ®¶óÁ¦³×Ä«´Â "Çѱ¹¿¡¼­ÀÇ ÀÌ·¹»ç Åõ¾à °á°ú´Â ±âÁ¸ È­Çпä¹ýÀ¸·Î´Â ´õÀÌ»ó Ä¡·áÇÒ ¼ö ¾ø´Â ³­Ä¡¼º ¸»±â Æó¾ÏȯÀÚµéÀ» ´ë»óÀ¸·Î ÀÌ·ïÁø °ÍÀ¸·Î Á¤½Ä ÀÓ»ó½ÃÇè°á°ú°¡ ¾Æ´Ï´Ù"¸é¼­ "ÀÌ¿¡ µû¶ó ÀÌ °á°ú¸¦ °¡Áö°í ÀÌ·¹»çÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ»¼Ó´ÜÇؼ­´Â ¾ÈµÈ´Ù"°í ¸»Çß´Ù.

...........................
5 July 2002
ASTRAZENECA SECURES FIRST MARKET APPROVAL FOR
IRESSA¢â IN JAPAN

AstraZeneca announced today that 'Iressa' (ZD1839, gefitinib) 250 mg once daily has received approval for the treatment of inoperable or recurrent non-small cell lung cancer (NSCLC) from the Japanese Ministry of Health, Labour and Welfare (MHLW), making Japan the first country worldwide to licence the drug. 'Iressa' is the first in a new class of anti-cancer drugs, known as Epidermal Growth Factor Receptor (EGFR) inhibitors, to become commercially available.

"The speed with which the Japanese MHLW have approved 'Iressa' is very encouraging and reinforces our confidence in this drug as a crucial advance in the treatment of lung cancer," said Sir Tom McKillop, Chief Executive Officer, AstraZeneca PLC. "With the US approval expected in the second half of this year, and further markets to follow, 'Iressa' will play a crucial role in AstraZeneca's business transformation moving forward."

The Japanese regulatory authorities have recently re-engineered the new drug application review procedure, which historically has been seen as somewhat slower than other regulatory bodies worldwide. The 'Iressa' review, which is the fastest on record (besides that for an AIDS treatment), is among the first to benefit from the new system. 'Iressa' will be the first drug in the world to be simultaneously developed in Japan, the United States and Europe, and launched in Japan first. AstraZeneca is the second fastest-growing major pharmaceutical company and ranks first in the oncology market in Japan, the world's second largest pharmaceutical market.

NSCLC killed close to a million people worldwide in 2000 alone. Each year in Japan, there are 50,000 patients with NSCLC, of which 43,000 will die. The Japanese MHLW is forecasting an 80 per cent increase in the incidence of lung cancer in Japan over the next 15 years. The worldwide market for lung cancer is currently worth approximately $1.6 billion, the majority of which is accounted for by NSCLC, and is scheduled to grow to $8 billion by 2011.

AstraZeneca anticipates full reimbursement for 'Iressa' by the end of the third quarter. Product launch is expected in the second half of this year in the United States, while regulatory reviews in Switzerland and Australia are currently underway. The first approval of 'Iressa' is based on data from two pivotal phase II trials, IDEAL 1 and 2. Results from these studies confirm 'Iressa' as an effective treatment for many patients with inoperable or recurrent NSCLC, with an acceptable tolerability profile with the majority of side effects (diarrhoea and skin rash) reported as mild and reversible. 'Iressa' is administered as a once daily, oral tablet.

Commenting on today's announcement from the MHLW, lead 'Iressa' trial investigator, Dr. M. Fukuoka, from the Kinki University School of Medicine, Osaka, Japan, said, "The introduction of 'Iressa' in Japan will be welcomed by both physicians and patients fighting this devastating disease. Most people already have advanced lung cancer by the time they are diagnosed, and even with the best treatment available at present, only 1 in 10 people with lung cancer will survive 5 years, compared with almost three quarters of women with breast cancer, so new treatment options like 'Iressa' are desperately needed. We know that 'Iressa' can benefit non-small cell lung cancer patients, and that it is well tolerated. Patients will be able to take 'Iressa' as a tablet and will not be subjected to the same side effects seen with chemotherapy."

'Iressa' is leading a new class of anti-cancer drugs known as epidermal growth factor receptor (EGFR) inhibitors. This targeted mode of action is different from cytotoxic chemotherapies and 'Iressa' is not causally associated with the same types of side effects such as alopecia, neutropenia or other haematological toxicity. Within the cell, 'Iressa' targets and blocks signalling pathways that are implicated in the growth and survival of cancer cells. These pathways appear to play a major role in the growth of many solid tumours; therefore, 'Iressa' may have therapeutic potential in a broad range of common cancers.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $16.4 billion and leading positions in sales of oncology, gastrointestinal, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products.
....................................